Type 2 Diabetes & Cardiorenal Axis
India is the diabetes capital of the world with over 101 million diagnosed individuals and 136 million with prediabetes. The unique Indian "thin-fat phenotype" causes vascular collapse and renal failure 1–2 decades earlier than Western baselines. Silicon Arm models multi-organ cardiorenal progression and hepatic crosstalk to de-risk next-generation metabolic therapeutics.
The Indian "Thin-Fat" Phenotype Challenge
Indian patients develop profound insulin resistance and accelerated pancreatic beta-cell decay at low BMI thresholds (BMI < 23 kg/m²), driven by disproportionately high visceral and hepatic fat deposits despite normal subcutaneous fat.
Western clinical trial protocols fail to predict the aggressive rate of microvascular deterioration (diabetic nephropathy, retinopathy) and early cardiorenal collapse in Indian cohorts.
Cardiorenal Endpoints & Multi-Organ Crosstalk
Creating population-calibrated virtual diabetic cohorts to accurately model cardiorenal decay, beta-cell preservation, and liver-pancreas metabolic interactions.
- • Virtual Cohorts for Thin-Fat Phenotype: Anchoring priors on visceral adiposity, hepatic steatosis, and accelerated beta-cell exhaustion.
- • Cardiorenal Progression Simulation: Modeling multi-year eGFR decline, microalbuminuria transitions, and 5-year MACE risk curves.
- • NAFLD-Diabetes Crosstalk: Simulating dual-action metabolic therapeutics (SGLT-2, GLP-1/GIP co-agonists, dual PPARs) across liver and kidney tissue compartments.
- • Glycemic Variability & Hypo Margins: Predicting hypoglycemia risk margins under novel combination regimens across variable nutritional baselines.
Beta-Cell Preservation Kinetics
Mathematical modeling of pancreatic island survival under chronic glucotoxicity and lipotoxic stress, predicting durability of glycemic response over 5 years.
Renal eGFR Preservation
Simulating intraglomerular hemodynamics and SGLT-2 mediated tubuloglomerular feedback to quantify long-term nephroprotection and delay to dialysis.
Hepatic-Pancreatic Synergy
Coupling hepatic steatosis reduction with insulin sensitivity rebound to predict sustained weight loss and glycemic remissions in non-obese Indian patients.
CDSCO Trial Endpoint Optimization
Optimize trial powering for composite cardiorenal endpoints, enabling clinical sponsors to demonstrate clear statistical superiority with smaller physical patient cohorts.
5-Year Cardiorenal Trajectory & eGFR Deceleration Simulator
Observe in-silico simulated long-term renal preservation and major adverse cardiovascular event (MACE) risk reduction under standard vs. novel dual-action metabolic therapies.
In-silico trial simulation models profound glycemic suppression alongside systemic cardiorenal protection. Reduced intraglomerular filtration pressure slows annual eGFR loss from -3.8 mL/min/year down to -1.4 mL/min/year, effectively deferring dialysis by 6.8 years and cutting microalbuminuria progression by 52%.